FDA
-
-
-
-
-
-
-
Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
-
-
-
-
-
-
-
FDA extends Capricor's deramiocel review deadline to November 2026
-
-
-
-
-
-
-
Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
-
-
-
-
-
-
-
CAPR INVESTIGATION: Block & Leviton Seeks to Speak With Capricor Therapeutics Investors
-
-
-
-
-
-
-
CAPR INVESTIGATION: Capricor Therapeutics Investors Should Contact Block & Leviton About Recovering Their Losses
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Falls 26% Following FDA Briefing Docs Post
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
333,420 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


